HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for BridgeBio Pharma (NASDAQ:BBIO) and maintained a price target of $43.
October 02, 2024 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for BridgeBio Pharma and maintained a price target of $43, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $43 price target by HC Wainwright & Co. suggests positive sentiment and confidence in BridgeBio Pharma's future performance. This could lead to a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100